Forte Capital LLC ADV decreased its position in Novartis AG (NYSE:NVS) by 8.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,600 shares of the company’s stock after selling 250 shares during the period. Forte Capital LLC ADV’s holdings in Novartis AG were worth $217,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Fisher Asset Management LLC increased its position in Novartis AG by 6.3% in the second quarter. Fisher Asset Management LLC now owns 6,505,935 shares of the company’s stock worth $543,050,000 after buying an additional 384,262 shares during the period. Trust Co. of Toledo NA OH increased its position in Novartis AG by 7.0% in the second quarter. Trust Co. of Toledo NA OH now owns 27,616 shares of the company’s stock worth $2,305,000 after buying an additional 1,798 shares during the period. Trust Co. of Vermont increased its position in Novartis AG by 3.3% in the second quarter. Trust Co. of Vermont now owns 110,651 shares of the company’s stock worth $9,236,000 after buying an additional 3,508 shares during the period. Northstar Group Inc. increased its position in Novartis AG by 18.3% in the second quarter. Northstar Group Inc. now owns 4,525 shares of the company’s stock worth $378,000 after buying an additional 700 shares during the period. Finally, Union Bankshares Corp increased its position in Novartis AG by 0.3% in the second quarter. Union Bankshares Corp now owns 37,521 shares of the company’s stock worth $3,132,000 after buying an additional 99 shares during the period. 11.27% of the stock is owned by hedge funds and other institutional investors.

Shares of Novartis AG (NVS) traded down 0.56% during midday trading on Monday, hitting $84.49. The stock had a trading volume of 448,129 shares. The company’s 50 day moving average is $83.64 and its 200 day moving average is $78.07. The firm has a market cap of $197.95 billion, a P/E ratio of 30.85 and a beta of 0.73. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The business’s revenue was down 1.8% on a year-over-year basis. On average, equities analysts predict that Novartis AG will post $4.75 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Forte Capital LLC ADV Sells 250 Shares of Novartis AG (NYSE:NVS)” was reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/07/forte-capital-llc-adv-sells-250-shares-of-novartis-ag-nysenvs.html.

A number of research firms have weighed in on NVS. BidaskClub raised Novartis AG from a “sell” rating to a “hold” rating in a research report on Saturday. Morgan Stanley raised Novartis AG from an “underweight” rating to an “overweight” rating in a research report on Wednesday, July 26th. Cowen and Company reaffirmed a “hold” rating on shares of Novartis AG in a research report on Tuesday, July 18th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a research report on Monday, July 17th. Finally, Zacks Investment Research downgraded Novartis AG from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company. Novartis AG has an average rating of “Hold” and a consensus target price of $81.71.

In other Novartis AG news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the business’s stock in a transaction on Wednesday, July 5th. The shares were acquired at an average price of $15.00 per share, with a total value of $4,000,005.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.01% of the stock is currently owned by insiders.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.